DelveInsight’s “HER2-Positive Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the HER2-Positive Gastric Cancer, historical and forecasted epidemiology as well as the HER2-Positive Gastric Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the HER2-Positive Gastric Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2-Positive Gastric Cancer Market Forecast
Some of the key facts of the HER2-Positive Gastric Cancer Market Report:
- The HER2-Positive Gastric Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Since more than ten years ago, ENHERTU is the first HER2-directed treatment for gastric cancer to receive EU approval
- Off-the-shelf natural killer (NK) cell therapy CYNK-101 received Orphan Drug Designation from the FDA in February 2022 as a potential treatment for patients with advanced HER2-positive stomach or gastroesophageal junction (GEJ) adenocarcinoma
- Approximately 51,000 cases of HER2-positive gastric cancer were reported incidentally in 7MM overall in 2022, and this number is anticipated to rise during the prediction period (2023–2032)
- In 2022, there were almost 5,800 incident cases of HER2-positive stomach cancer in the United States. A total of about 12,000 incident cases occurred in the EU4 and UK region
- About 3,600 men and 2,200 women in the United States will be diagnosed with HER2-positive gastric cancer in 2022
- The age group of 75 years and older was shown to have the highest incidence of HER2-positive gastric cancer cases. In this age range, there were over 17,000 incident instances in Japan in 2022. It is projected that at the conclusion of the prediction period, this count would rise.
- Key HER2-Positive Gastric Cancer Companies: Zymeworks, Pieris Pharmaceutical, BioInvent International AB, Shanghai Miracogen, Pieris Pharmaceuticals, Inc., Yuhan Corporation, BioInvent International AB, Pfizer, Hanmi Pharma, Bristol-Myers Squibb, Shanghai JMT-Bio Inc., Merck Sharp & Dohme LLC, Hoffmann-La Roche, and others
- Key HER2-Positive Gastric Cancer Therapies: Zanidatamab, Cinrebafusp alfa, BI-1607, MRG002, Cinrebafusp alfa (PRS-343), YH32367, BI-1607, PF00299804, HM781-36B(Poziotinib), BDC-1001, Paclitaxel Injection, Cisplatin, Pertuzumab, and others
- The HER2-Positive Gastric Cancer epidemiology based on gender analyzed that HER2-Positive Gastric Cancer is more common in males than females
- The HER2-Positive Gastric Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2-Positive Gastric Cancer pipeline products will significantly revolutionize the HER2-Positive Gastric Cancer market dynamics.
HER2-Positive Gastric Cancer Overview
The stomach lining can develop malignant (cancer) cells, which is a condition known as gastric cancer (GC). It is a tumour that is physiologically diverse. Human epidermal growth factor receptor-2 (HER2) biomarker overexpression in GC was found to be a significant step towards understanding the disease’s molecular complexity.
Get a Free sample for the HER2-Positive Gastric Cancer Market Report
https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market
HER2-Positive Gastric Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
HER2-Positive Gastric Cancer Epidemiology Segmentation:
The HER2-Positive Gastric Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of HER2-Positive Gastric Cancer
- Prevalent Cases of HER2-Positive Gastric Cancer by severity
- Gender-specific Prevalence of HER2-Positive Gastric Cancer
- Diagnosed Cases of Episodic and Chronic HER2-Positive Gastric Cancer
Download the report to understand which factors are driving HER2-Positive Gastric Cancer epidemiology trends @ HER2-Positive Gastric Cancer Epidemiology Forecast
HER2-Positive Gastric Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2-Positive Gastric Cancer market or expected to get launched during the study period. The analysis covers HER2-Positive Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the HER2-Positive Gastric Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
HER2-Positive Gastric Cancer Therapies and Key Companies
- Zanidatamab: Zymeworks
- Cinrebafusp alfa: Pieris Pharmaceutical
- BI-1607: BioInventInternational AB
- MRG002: Shanghai Miracogen
- Cinrebafusp alfa (PRS-343): Pieris Pharmaceuticals, Inc.
- YH32367: Yuhan Corporation
- BI-1607: BioInvent International AB
- PF00299804: Pfizer
- HM781-36B(Poziotinib): Hanmi Pharma
- BDC-1001: Bristol-Myers Squibb
- Paclitaxel Injection: Shanghai JMT-Bio Inc.
- Cisplatin: Merck Sharp & Dohme LLC
- Pertuzumab: Hoffmann-La Roche
Discover more about therapies set to grab major HER2-Positive Gastric Cancer market share @ HER2-Positive Gastric Cancer Treatment Market
HER2-Positive Gastric Cancer Market Strengths
- In-depth understanding of molecular heterogeneity of tumor and pathogenesis will further lead to the novel therapies
- More targeted therapies are in pipeline
HER2-Positive Gastric Cancer Market Opportunities
- Future development of potential biomarkers may improve screening and early detection of gastric cancers, with better accuracy, in the future
- Increase in the awareness of gastric cancers and encouraging regular screening
Scope of the HER2-Positive Gastric Cancer Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key HER2-Positive Gastric Cancer Companies: Zymeworks, Pieris Pharmaceutical, BioInvent International AB, Shanghai Miracogen, Pieris Pharmaceuticals, Inc., Yuhan Corporation, BioInvent International AB, Pfizer, Hanmi Pharma, Bristol-Myers Squibb, Shanghai JMT-Bio Inc., Merck Sharp & Dohme LLC, Hoffmann-La Roche, and others
- Key HER2-Positive Gastric Cancer Therapies: Zanidatamab, Cinrebafusp alfa, BI-1607, MRG002, Cinrebafusp alfa (PRS-343), YH32367, BI-1607, PF00299804, HM781-36B(Poziotinib), BDC-1001, Paclitaxel Injection, Cisplatin, Pertuzumab, and others
- HER2-Positive Gastric Cancer Therapeutic Assessment: HER2-Positive Gastric Cancer current marketed and HER2-Positive Gastric Cancer emerging therapies
- HER2-Positive Gastric Cancer Market Dynamics: HER2-Positive Gastric Cancer market drivers and HER2-Positive Gastric Cancer market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- HER2-Positive Gastric Cancer Unmet Needs, KOL’s views, Analyst’s views, HER2-Positive Gastric Cancer Market Access and Reimbursement
To know more about HER2-Positive Gastric Cancer companies working in the treatment market, visit @ HER2-Positive Gastric Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
1. HER2-Positive Gastric Cancer Market Report Introduction
2. Executive Summary for HER2-Positive Gastric Cancer
3. SWOT analysis of HER2-Positive Gastric Cancer
4. HER2-Positive Gastric Cancer Patient Share (%) Overview at a Glance
5. HER2-Positive Gastric Cancer Market Overview at a Glance
6. HER2-Positive Gastric Cancer Disease Background and Overview
7. HER2-Positive Gastric Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of HER2-Positive Gastric Cancer
9. HER2-Positive Gastric Cancer Current Treatment and Medical Practices
10. HER2-Positive Gastric Cancer Unmet Needs
11. HER2-Positive Gastric Cancer Emerging Therapies
12. HER2-Positive Gastric Cancer Market Outlook
13. Country-Wise HER2-Positive Gastric Cancer Market Analysis (2019–2032)
14. HER2-Positive Gastric Cancer Market Access and Reimbursement of Therapies
15. HER2-Positive Gastric Cancer Market Drivers
16. HER2-Positive Gastric Cancer Market Barriers
17. HER2-Positive Gastric Cancer Appendix
18. HER2-Positive Gastric Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services